Inpatient Rehab Doesn't Up Total Knee Arthroplasty Outcomes

Share this content:
Inpatient Rehab Doesn't Up Total Knee Arthroplasty Outcomes
Inpatient Rehab Doesn't Up Total Knee Arthroplasty Outcomes

WEDNESDAY, March 15, 2017 (HealthDay News) -- The use of inpatient rehabilitation in addition to home-based rehabilitation does not improve mobility at 26 weeks after total knee arthroplasty, according to a study published in the March 14 issue of the Journal of the American Medical Association.

Mark A. Buhagiar, from Braeside Hospital in Prairiewood, Australia, and colleagues conducted a two-group, parallel, randomized clinical trial involving patients with osteoarthritis undergoing primary total knee arthroplasty. The authors randomized 81 patients to receive 10 days of hospital inpatient rehabilitation followed by an eight-week clinician-monitored home-based program, 84 to receive the home-based program alone, and 87 to be in an observational group, which received the home-based program.

The researchers observed no significant difference in the six-minute walk test between the inpatient rehabilitation and either of the home program groups at 26 weeks after surgery (mean difference, −1.01; 95 percent confidence interval [CI], −25.56 to 23.55) or in patient-reported pain and function or quality of life (knee score mean difference, 2.06; 95 percent CI, −0.59 to 4.71; EuroQol Group 5-Dimension Self-Report Questionnaire visual analogue scale mean difference, 1.41; 95 percent CI, −6.42 to 3.60). For the inpatient group the number of post-discharge complications was 12, versus nine among the home group; no adverse events were reported as a result of trial participation.

"These findings do not support inpatient rehabilitation for this group of patients," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »